Track topics on Twitter Track topics that are important to you
Nortech Systems Incorporated (Nasdaq: NSYS), a leading provider of design and manufacturing solutions for complex electromechanical products, reported net sales of $28.2 million for the first quarter ended March 31, 2019, compared with $26.4 million for the first quarter of 2018.
Operating loss for the first quarter of 2019 was $104,000, which compares with an operating loss of $120,000 for the first quarter of 2018. Net loss for the first quarter of 2019 was $363,000, or $0.14 per diluted common share. This compares with a net loss for first quarter of 2018 of $391,000, or $0.14 per diluted common share.
The mission of Nortech Systems is to be the most trusted, innovative, and nimble design and manufacturing services and solutions provider, while taking great care of its employees, customers, and supplier partners.
About Nortech Systems Incorporated
Nortech Systems is a leading provider of design and manufacturing solutions for complex electromechanical systems, assemblies, and components. Nortech Systems primarily serves the medical, aerospace & defense, and industrial markets. Its design services span concept development to commercial design, and include software, electrical, mechanical, and biomedical engineering. Its manufacturing and supply chain capabilities are vertically integrated around wire/cable/interconnect assemblies, printed circuit board assemblies, as well as system-level assembly, integration, and final test. Headquartered in Maple Grove, Minn., Nortech currently has seven manufacturing locations and design centers across the U.S., Latin America, and Asia. Nortech Systems is traded on the NASDAQ Stock Market under the symbol NSYS. Nortech’s website is www.nortechsys.com.
This press release contains forward-looking statements made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. While this release is based on management’s best judgment and current expectations, actual results may differ and involve a number of risks and uncertainties. Important factors that could cause actual results to differ materially from the forward-looking statements include, without limitation: volatility in market conditions which may affect market supply of and demand for the company’s products; increased competition; changes in the reliability and efficiency of operating facilities or those of third parties; risks related to availability of labor; commodity and energy cost instability; general economic, financial and business conditions that could affect the company’s financial condition and results of operations; as well as risk factors listed from time to time in the company’s filings with the SEC.
Condensed Consolidated Statements of Operations
|THREE MONTHS ENDED|
|Cost of Goods Sold||25,204||23,419|
|General and Administrative Expenses||2,304||2,109|
|Total Operating Expenses||3,065||3,148|
|Loss From Operations||(104||)||(120||)|
|Loss Before Income Taxes||(349||)||(292||)|
|Income Tax Expense||14||99|
|Loss Per Common Share - Diluted||$||(0.14||)||$||(0.14||)|
|Weighted Average Number of Common Shares Outstanding - Diluted||2,659,859||2,720,609|
Condensed Consolidated Balance Sheets
|MARCH 31, 2019||DECEMBER 31, 2018|
|Prepaid Expenses and Other Current Assets||2,133||1,381|
|Property and Other Long-term Assets||9,886||10,178|
|Goodwill and Other Long-term Assets, Net||9,260||3,926|
|Other Current Liabilities||7,004||6,750|
|Long Term Line of Credit||11,294||9,264|
|Long-term Debt and Other Long-term Liabilities||9,308||4,714|
|Total Liabilities and Shareholders’ Equity||$||69,676||$||59,960|
Connie Beck, VP & CFO
Nortech Systems Incorporated
Brookside Communications Group
(952) 920-3908 or firstname.lastname@example.org
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...